Bexson Biomedical
Dr. Becker has over 20 years of research and clinical experience in NMDA-receptor pharmacology and clinical use. He was one of the first MDs in U.S. administering and documenting ketamine for depression in the clinic, and is a world recognized speaker and expert in the clinical use of ketamine. His expertise led to development of an effective nutraceutical product addressing NMDA-receptor abnormalities. He received his B.S. from UC Berkeley and M.D from UCLA. He maintains a clinical practice focused in Functional Psychiatry and novel treatment approaches to mental health challenges.
This person is not in any offices
Bexson Biomedical
2 followers
Bexson Biomedical is developing non-opioid therapies for pain management. Their goal is to provide therapies that provide relief to patients and reduce the rates of opioid addiction.